Pfizer lifts 2026 revenue outlook after "another strong quarter"
Pfizer Inc on Tuesday lifted its annual revenue guidance after a second quarter boost from its recently launched or acquired products.
The New York-based biopharmaceutical company reported a net loss of USD248 million in the second quarter of the year, swinging from profit of USD2.91 billion. Pfizer reported asset impairments of USD4.33 billion, up markedly from USD93 million a year prior.
It reported a diluted loss per share of USD0.04, swinging from an EPS of USD0.51. On an adjusted basis, it posted a diluted EPS of USD0.77, down slightly from USD0.78.
Revenue rose 2.6% to USD15.03 billion from USD14.65 billion a year prior.
"Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy. Our launched and acquired products performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength. I am confident we will create substantial future value for patients and shareholders," Chief Executive Officer Albert Bourla said.
Launched products are those that have been unveiled recently.
Looking ahead, Pfizer now expects annual revenue between USD60.5 billion and USD62.5 billion, its outlook improved from a USD59.5 billion to USD62.5 billion range. Revenue in 2025 amounted to USD62.58 billion, so the guidance suggests a flat to lower 2026.
Pfizer maintained its USD2.80 to USD3.00 adjusted diluted EPS view, which would represent a decline from USD3.22 in 2025.
"The 2026 full-year revenue guidance reflects better than expected performance of the non-Covid products by approximately USD1.5 billion and the revised revenue expectation for our Covid-19 products, down to approximately USD4 billion from approximately USD5 billion previously," Pfizer said.
Pfizer shares were 0.2% lower at USD24.99 in pre-market dealings in New York on Tuesday.
Copyright 2026 Alliance News Ltd. All Rights Reserved.